"Rattaché au Pôle Lille Métropole, l’Hôpital privé La Louvière, établissement du groupe Ramsay Santé, offre aux patients une prise en charge complète et personnalisée. En partenariat avec l’hôpital privé de Villeneuve d’Ascq, il dispense des soins de qualité en chirurgie, en médecine et en cancérologie. L’établissement dispose de plateaux médico-techniques de référence, et d’outils de diagnostic et de traitement de pointe extrêmement performants."

During the past decade, Hôpital Privé La Louvière conducted 25 clinical trials. In the 10-year time frame, 25 clinical trials started and 7 clinical trials were completed, i.e. on average, 28% percent of trials that started reached the finish line to date. In the past 5 years, 9 clinical trials started and 4 clinical trials were completed. i.e. 44.4% of trials that started reached the finish line.

Out of the total clinical trials conducted in "Hôpital Privé La Louvière" #1 sponsor was "Pfizer" with 8 trials, followed by "Ramsay Générale de Santé" with 3 trials sponsored, "University Hospital, Lille" with 3 trials sponsored, "Clovis Oncology, Inc." with 2 trials sponsored and "Fédération Française de Pneumologie" with 2 trials sponsored. Other sponsors include 11 different institutions and companies that sponsored additional 20 trials in total.

In terms of collaborators to trials, out of the total clinical trials conducted in "Hôpital Privé La Louvière" #1 collaborator was "European Clinical Trial Experts Network" with 2 trials as a collaborator, "Federation of Medical Specialties" with 2 trials as a collaborator, "Foundation Medicine" with 2 trials as a collaborator, "Air Liquide SA" with 1 trials as a collaborator and "CSL Behring" with 1 trials as a collaborator. Other collaborators include 4 different institutions and companies that were collaborators in the rest 14 trials.

According to Clinical.Site data, the most researched conditions in "Hôpital Privé La Louvière" are "Cardiovascular Disease" (2 trials), "Metastatic Castration Resistant Prostate Cancer" (2 trials), "Obesity" (2 trials), "Obstructive Sleep Apnea" (2 trials) and "Prostate Cancer" (2 trials). Many other conditions were trialed in "Hôpital Privé La Louvière" in a lesser frequency.

Most popular intervention types in "Hôpital Privé La Louvière" are "Drug" (12 trials), "Device" (8 trials), "Other" (5 trials), "Procedure" (4 trials) and "Behavioral" (1 trials). Other intervention types were less common.

The name of intervention was led by "Placebo" (2 trials), "Rucaparib" (2 trials), "bococizumab (PF-04950615)" (2 trials), "Abiraterone acetate or Enzalutamide or Docetaxel" (1 trials) and "Adaptative Servo Ventilation" (1 trials). Other intervention names were less common.

The vast majority of trials in "Hôpital Privé La Louvière" are 29 trials for "All" genders, 4 trials for "Male" genders and 1 trials for "Female" genders.

Currently, there are NaN active trials in "Hôpital Privé La Louvière". 1 are not yet recruiting, 7 are recruiting, 3 are Active, not recruiting, and undefined are Enrolling by invitation. In total, there were 15 completed trials in Hôpital Privé La Louvière, undefined suspended trials, and 5 terminated clinical trials to date.

Out of the total trials that were conducted in Hôpital Privé La Louvière, 0 "Phase 1" clinical trials were conducted, 3 "Phase 2" clinical trials and 7 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 3 trials, and there were also 10 trials that are defined as “Not Applicable".